Hepatitis C is treated with combination DAA regimens rather than a single drug. Common examples include ledipasvir/sofosbuvir (Harvoni) and glecaprevir/pibrentasvir (Mavyret/Maviret). Components such as sofosbuvir also appear in multiple combination products. The appropriate regimen depends on cirrhosis status, prior treatment history, and interaction risk, so medication names are informational—selection should be clinician-guided.